537 related articles for article (PubMed ID: 33752671)
1. Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.
Shin YD; Lee HM; Choi YJ
BMC Surg; 2021 Mar; 21(1):159. PubMed ID: 33752671
[TBL] [Abstract][Full Text] [Related]
2. Is Sentinel Lymph Node Biopsy Necessary for Ductal Carcinoma In Situ Patients Undergoing Mastectomy?
Miller-Ocuin JL; Howard-McNatt M; Levine EA; Chiba A
Am Surg; 2020 Aug; 86(8):955-957. PubMed ID: 32862671
[TBL] [Abstract][Full Text] [Related]
3. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy.
Chin-Lenn L; Mack LA; Temple W; Cherniak W; Quinn RR; Ravani P; Lewin AM; Quan ML
Ann Surg Oncol; 2014 Jan; 21(1):66-73. PubMed ID: 24046105
[TBL] [Abstract][Full Text] [Related]
4. Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
Ramzi S; Najeeb E; Coulthard J; Jenkins S
Breast Cancer Res Treat; 2020 Jul; 182(1):47-54. PubMed ID: 32430678
[TBL] [Abstract][Full Text] [Related]
5. Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ.
Munck F; Clausen EW; Balslev E; Kroman N; Tvedskov TF; Holm-Rasmussen EV
Br J Surg; 2020 Jan; 107(1):96-102. PubMed ID: 31823362
[TBL] [Abstract][Full Text] [Related]
6. Sentinel lymph node positivity in patients undergoing mastectomies for ductal carcinoma in situ (DCIS).
Price A; Schnabel F; Chun J; Kaplowitz E; Goodgal J; Guth A; Axelrod D; Shapiro R; Mema E; Moy L; Darvishian F; Roses D
Breast J; 2020 May; 26(5):931-936. PubMed ID: 31957944
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of axillary positive sentinel lymph node biopsy in extended ductal carcinoma in situ treated by simple mastectomy at once.
Hotton J; Salleron J; Rauch P; Buhler J; Pierret M; Baumard F; Leufflen L; Marchal F
J Gynecol Obstet Hum Reprod; 2020 Mar; 49(3):101641. PubMed ID: 31562936
[TBL] [Abstract][Full Text] [Related]
8. Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified?
Sorrentino L; Sartani A; Bossi D; Amadori R; Nebuloni M; Truffi M; Bonzini M; Riggio E; Foschi D; Corsi F
Breast J; 2018 May; 24(3):325-333. PubMed ID: 29024241
[TBL] [Abstract][Full Text] [Related]
9. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases.
Goyal A; Douglas-Jones A; Monypenny I; Sweetland H; Stevens G; Mansel RE
Breast Cancer Res Treat; 2006 Aug; 98(3):311-4. PubMed ID: 16552627
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
van Roozendaal LM; Goorts B; Klinkert M; Keymeulen KBMI; De Vries B; Strobbe LJA; Wauters CAP; van Riet YE; Degreef E; Rutgers EJT; Wesseling J; Smidt ML
Breast Cancer Res Treat; 2016 Apr; 156(3):517-525. PubMed ID: 27083179
[TBL] [Abstract][Full Text] [Related]
11. Axillary evaluation is not warranted in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy.
Si J; Guo R; Huang N; Xiu B; Zhang Q; Chi W; Wu J
Cancer Med; 2019 Dec; 8(18):7586-7593. PubMed ID: 31660702
[TBL] [Abstract][Full Text] [Related]
12. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
[TBL] [Abstract][Full Text] [Related]
13. The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study.
Holm-Rasmussen EV; Jensen MB; Balslev E; Kroman N; Tvedskov TF
Eur J Cancer; 2017 Dec; 87():1-9. PubMed ID: 29096155
[TBL] [Abstract][Full Text] [Related]
14. Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy.
Watanabe Y; Anan K; Saimura M; Koga K; Fujino M; Mine M; Tamiya S; Nishihara K; Nakano T; Mitsuyama S
Breast Cancer; 2018 Nov; 25(6):663-670. PubMed ID: 29786772
[TBL] [Abstract][Full Text] [Related]
15. A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged From Ductal Carcinoma in Situ.
Yoo TK; Kim SJ; Lee J; Lee SB; Lee SJ; Park HY; Park HK; Chae BJ; Eom YH; Kim HS; Song BJ
Clin Breast Cancer; 2020 Jun; 20(3):e281-e289. PubMed ID: 32147404
[TBL] [Abstract][Full Text] [Related]
16. Utilization of Axillary Surgery for Patients With Ductal Carcinoma In Situ: A Report From the National Cancer Data Base.
Miller ME; Kyrillos A; Yao K; Kantor O; Tseng J; Winchester DJ; Shulman LN
Ann Surg Oncol; 2016 Oct; 23(10):3337-46. PubMed ID: 27334212
[TBL] [Abstract][Full Text] [Related]
17. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy.
Mittendorf EA; Arciero CA; Gutchell V; Hooke J; Shriver CD
Curr Surg; 2005; 62(2):253-7. PubMed ID: 15796952
[TBL] [Abstract][Full Text] [Related]
18. Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates.
Bae SJ; Kook Y; Jang JS; Baek SH; Moon S; Kim JH; Lee SE; Kim MJ; Ahn SG; Jeong J
Breast Cancer Res; 2024 Apr; 26(1):65. PubMed ID: 38609935
[TBL] [Abstract][Full Text] [Related]
19. Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy.
Huang NS; Si J; Yang BL; Quan CL; Chen JJ; Wu J
Cancer Med; 2018 Jan; 7(1):56-63. PubMed ID: 29271113
[TBL] [Abstract][Full Text] [Related]
20. Sentinel Node Procedure Obsolete in Lumpectomy for Ductal Carcinoma In Situ.
Heymans C; van Bastelaar J; Visschers RGJ; Vissers YLJ
Clin Breast Cancer; 2017 Jun; 17(3):e87-e93. PubMed ID: 28162949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
